Optimizing Betalactam Clinical Response by Using a Continuous Infusion: A Comprehensive Review

Area of Science:

• Infectious Diseases
• Pharmacology
• Critical Care Medicine

Background:

• Antimicrobial resistance poses a significant global health threat, contributing to substantial mortality.
• Pharmacokinetic/pharmacodynamic (PK/PD) data suggest advantages for continuous infusion strategies.
• Optimizing clinical practice necessitates a review of existing clinical data on betalactam infusion methods.

Purpose of the Study:

• To review and synthesize clinical data comparing continuous or extended infusion versus intermittent infusion of betalactam antibiotics.
• To evaluate the clinical efficacy of different betalactam administration strategies.
• To inform clinical practice guidelines for betalactam antibiotic use.

Main Methods:

• A comprehensive literature review was conducted using the Medline database.
• Studies comparing continuous or extended infusion with intermittent infusion of betalactams were included.
• Clinical data from the reviewed literature were analyzed.

Main Results:

• Clinical studies indicate that continuous infusion of betalactams is comparable in efficacy to intermittent infusion for the general patient population.
• A subset analysis revealed that continuous infusion was associated with improved clinical response in critically ill patients.
• Patients with infections caused by organisms with a high minimum inhibitory concentration (MIC) also demonstrated better outcomes with continuous infusion.

Conclusions:

• Clinical evidence supports the use of continuous infusion for betalactams, particularly in severely ill patients or those with high-MIC infections, correlating with enhanced survival rates.
• Continuous infusion may enable a reduction in daily antibiotic dosage, potentially leading to decreased healthcare costs.
• The findings align with PK/PD data, reinforcing the benefits of continuous infusion in specific patient populations.